GBR-12935 is a potent and selective dopamine reuptake inhibitor, belonging to the piperazine derivative class. Initially developed in its tritiated form, it was primarily used to map the distribution of dopaminergic neurons in the brain by selectively labeling dopamine transporter proteins. This application has been instrumental in the diagnosis of Parkinson’s disease, although more selective radioligands like Ioflupane (123I) are now preferred for this purpose. GBR-12935 is extensively utilized in animal research to investigate Parkinson’s disease and the dopamine pathways in the brain.
The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/GBR-12935
https://pubchem.ncbi.nlm.nih.gov/compound/11957553
https://www.medchemexpress.com/GBR-12935-dihydrochloride.html
https://www.medkoo.com/products/15862
https://www.sciencedirect.com/science/article/abs/pii/S0014299997010947
https://pubmed.ncbi.nlm.nih.gov/11230993/
